Moleculin Biotech Inc. has appointed Adriano Treve as a Strategic Advisor for partnerships. With over 40 years of experience at Roche, including executive roles in various regions, Treve will assist in advancing Moleculin's strategic partnerships as they progress in their Phase 2B/3 clinical trial of Annamycin for acute myeloid leukemia. This move is expected to enhance the company's strategic positioning and partnership opportunities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-022878), on July 17, 2025, and is solely responsible for the information contained therein.